By ReportBuyer, Special for USDR
Diabetes is rapidly gaining the status of a potential epidemic in India with around 65 million people currently being affected by it.
The Indian population that had faced under nutrition for a long time is now exposed to over nutrition and sedentary lifestyles. Coupled with a bad nutritional history and the fact that Indians are genetically more vulnerable to diabetes compared to other population groups, India’s struggle with diabetes is expected to be one of the biggest epidemics the country has ever witnessed.
Here are the some key findings of the study:
· India’s diabetes statistics may ring alarm bells for the government and healthcare authorities, for drug and diagnostic manufacturers, however, it represents a goldmine.
· Fuelled by a continuous increase in the healthcare expenditures, the market for diabetes drugs and diagnostics is expanding robustly in the country.
· The market for diabetes drugs and diagnostics create lucrative opportunities for global healthcare companies at a time when growth rates in the more developed markets have declined.
The report provides both current and future trends in the prevalence, demographical breakup, diagnosis and treatment of diabetes in India. The report has segmented the Indian diabetes market into three segments:
· Oral Antidiabetics
· Insulin
· Diabetes Diagnostics
For each of the aforementioned categories, the report provides historical and future market sales, performance of key classes and the performance of top players.
This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the Indian diabetes market in some form or the other.
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
SOURCE ReportBuyer
0
0